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Invasive fungal disease (IFD) is a major cause of morbidity and mortality after hematopoietic stem cell
transplantation (HCT). We performed a retrospective review of 271 adults with a hematologic malignancy
undergoing allogeneic HCT to determine the incidence of and risk factors for IFD and to examine the impact of
IFD on nonrelapse mortality and overall survival. We deﬁned IFD using standard criteria and selected proven
and probable cases for analysis. Diagnoses in the study group included acute leukemia (42%), non-Hodgkin
lymphoma (24%), myelodysplastic syndrome (15%), chronic lymphocytic leukemia (5%), and other hemato-
logic disorders (14%). Conditioning included reduced-intensity (64%) and myeloablative (36%) regimens.
Donor sources were HLA-matched sibling (60%), matched unrelated (20%), haploidentical (12%), and cord
blood (8%). A total of 51 episodes of IFD were observed in 42 subjects (15%). Aspergillus spp (47%) was the most
frequent causative organism, followed by Candida spp (43%). The majority of IFD cases (67%) were reported
after day þ100 post-HCT. In multivariate analysis, haploidentical donor transplantation (hazard ratio [HR],
3.82; 95% conﬁdence interval [CI], 1.49-9.77; P ¼ .005) and grade II-IV acute graft-versus-host disease (HR,
2.55; 95% CI, 1.07-6.10; P ¼ .03) were risk factors for the development of IFD. Conversely, higher infused
CD34þ cell dose was associated with a lower risk of IFD (HR, 0.80; 95% CI, 0.68-0.94; P ¼ .006, per 1  106
cells/kg increase in CD34þ cell infusion). IFD-related mortality was 33.3%. Nonrelapse mortality was signiﬁ-
cantly higher in patients who developed IFD compared with those without IFD (P < .001, log-rank test).
Patients with IFD had lower overall survival (5.8 months versus 76.1 months; P < .001, log-rank test). Further
studies exploring strategies to increase the infused cell dose and determine adequate prophylaxis, especially
against aspergillus, beyond day þ100 are needed.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION Non-albicans candidal species are more frequently observed
Invasive fungal disease (IFD) is a major cause of morbidity
and mortality after hematopoietic stem cell transplantation
(HCT) [1-9]. The reported incidence of IFD in allogeneic HCT
recipients has ranged from 6% to 33% in previous studies
[2-11]. Martino et al. [4] reported an incidence of 14% in 395
recipients of allogeneic HCT from HLA-matched sibling
donors. A much smaller study by Hagen et al. [5], involving
31 patients receiving nonmyeloablative allogeneic HCT,
found a 32% incidence of IFD.
Although routine administration of systemic antifungal
prophylaxis in the HCT setting signiﬁcantly reduces both the
incidence of proven IFD and IFD-related mortality, IFD
remains a potentially lethal complication afterHCT [12]. Since
the 1990s, after the use of ﬂuconazole for prophylaxis in HCT
became a routine, the incidence of invasive candidiasis has
decreased, to its current range of 1.1%-5% [2-4,11,13,14].edgments on page 1195.
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13.05.018than C albicans, and Aspergillus species have emerged as the
most frequently encountered fungal pathogen after alloge-
neic HCT [3,5,9,12,15]. The Transplant-Associated Infection
Surveillance Network (TRANSNET) database, currently the
most comprehensive multicenter epidemiologic surveillance
study of invasive fungal infections in transplantation, reports
a 1-year survival of 33% for invasive candidiasis afterHCT [11].
The multicenter Prospective Antifungal Therapy (PATH)
Alliance registry also reports high mortality in this patient
population, with a 12-week mortality of 49% after the diag-
nosis of invasive candidiasis [16]. Despite continuing
advances in treatment and supportive care, invasive asper-
gillosis after HCTalso carries a grave prognosis, with reported
mortality of 35%-67% [16-18]. The 1-year overall survival for
patients developing invasive aspergillosis after HCT was 25%
in the TRANSNET study [11].
Studies performed in the early 21st century have inves-
tigated factors for the development of IFD in HCT recipients.
Risk factors associated with IFD include older age, indwell-
ing catheter uses, chemotherapy-induced severe mucositis,
conditioning regimen, gastointestinal tract colonization,
prolonged neutropenia, graft source, cytomegalovirus (CMV)
infection, and graft-versus-host disease (GVHD) and chronicTransplantation.
Table 1
Patient Characteristics
Characteristic Value
Male sex, n (%) 152 (56)
Age, years, median (IQR) 53 (18-75)
Diagnosis, n (%)
Acute myelogenous leukemia 93 (34)
Non-Hodgkin lymphoma 64 (24)
Myelodysplastic syndrome 40 (15)
Acute lymphoblastic leukemia 21 (8)
Chronic lymphocytic leukemia 13 (5)
Myeloproliferative disorder 12 (4)
Hodgkin disease 11 (4)
Multiple myeloma 10 (4)
Other 7 (2)
Previous autologous HCT, n (%) 40 (15)
Previous IFD, n (%) 16 (6)
Diabetes mellitus, n (%) 29 (11)
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limited regarding the risk factors for IFD in adult patients
undergoing allogeneic HCT after both myeloablative and
reduced-intensity conditioning [21,22]. None of the afore-
mentioned studies explored the relationship between the
cell dose infused and development of IFD.
We undertook the present study to explore the incidence
of IFD after allogeneic HCT in a single center, determine the
risk factors for development of IFD, study the association of
cell dose with IFD, and analyze the impact of IFD on non-
relapse mortality (NRM) and overall survival (OS).
PATIENTS AND METHODS
To study the incidence, risk factors, and outcomes in patients who
developed IFD, we retrospectively analyzed the medical records of 300
consecutive adult patients (age 18 years) with a hematologic malignancy
undergoing allogeneic HCT at Massachusetts General Hospital between
2000 and 2010. Patients who had undergone previous allogeneic HCT or
combined bone marrow/kidney transplantation were excluded from our
analysis, but patients who had undergone previous autologous HCT were
included. Only the ﬁrst allogeneic HCT was analyzed for those who under-
went multiple transplantations. A total of 271 patients were included in the
ﬁnal analysis.
All patients received antifungal prophylaxis from the day before HCT up
to at least day þ100; 90% received ﬂuconazole 400 mg/day. Data are limited
on antifungal prophylaxis beforeHCT. Themajority of patientswith leukemia
received ﬂuconazole 200mg during induction chemotherapy, whereasmost
lymphoma patients did not receive routine antifungal prophylaxis during
preconditioning chemotherapy. During transplantation, routine anti-
infective prophylaxis was also provided by a ﬂuoroquinolone and acyclovir,
and Pneumocystis jiroveci prophylaxis was provided by trimethoprim-
sulfamethoxazole or another agent. Patients were screened weekly for
CMV, and ganciclovir therapy was started on the detection of CMV anti-
genemia. All patients were housed in rooms with high-efﬁciency particulate
air ﬁltration. Myeloablative conditioning consisted of either high-dose total
body irradiationebased regimens in combinationwith cyclophosphamide or
high-dose busulfanebased regimen, combined with cyclophosphamide.
Reduced-intensity conditioning regimenswere ﬂudarabine-based, including
ﬂudarabine and busulfan in most cases [23]. For double cord blood HCT, the
conditioning regimen consisted of ﬂudarabine, melphalan, and antithymo-
cyte globulin (ATG). GVHD prophylaxis was provided by tacrolimus or
cyclosporine plus methotrexate with or without ATG, sirolimus and tacroli-
mus, or cyclosporine andmycophenylatemofetil. This studywas undertaken
on approval from the Partners Institutional Review Board.
Deﬁnitions of IFD
We deﬁned IFD using the European Organization for Research and
Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the
National Institute of Allergy and Infectious Diseases Mycoses Study Group
Consensus Group deﬁnitions [24] and included proven and probable cases
for analysis. Proven IFD was deﬁned as evidence of fungal elements in
a sterile tissue specimen by microscopy and/or a positive culture obtained
either from peripheral blood or from needle aspirate or biopsy from nor-
mally sterile tissues. Probable IFD was deﬁned as isolation of fungal
elements in a nonsterile tissue (bronchoalveolar lavage ﬂuid or sputum) or
positive Galactomannan antigen or b-D-glucan test in patients with clinical
and radiologic features suggestive of IFD. We did not include patients with
possible IFD, deﬁned as those with clinical manifestations suggestive of IFD
but lacking mycologic evidence to support the diagnosis, in our analysis.
Neutrophil engraftment was deﬁned as the ﬁrst day of an absolute
neutrophil count (ANC) >500/mL for 2 consecutive days. Platelet engraft-
ment was deﬁned as the ﬁrst day of 3 consecutive platelet counts>20 109/
L over a period of at least 7 days, in the absence of platelet transfusion for at
least 7 days before this date. Acute GVHD (aGVHD) was graded according to
established criteria [25]. The Glucksberg grading systemwas used to classify
the maximum grade of aGVHD [26].
IFD-related mortality was deﬁned as death attributed to a direct
consequence of fungal infection (eg, respiratory failure due to fungal
pneumonia) or a direct complication of IFD (eg, bleeding or superimposed
bacterial infection and sepsis with unresolved fungal infection) in the
absence of relapse or progressive disease.
Statistical Analysis
Continuous data are reported as mean  SD, and time data are reported
as median (range or interquartile range [IQR]). Categorical data are reported
as frequency (%). NRMwas deﬁned as death not caused from disease relapse/progression and was estimated from the day of transplantation to death or
last follow-up, with the exception of patients who relapsed/progressed
(who were censored at the dates of relapse/progression) [27]. OS was
deﬁned as the time from transplantation to death from any cause.
Progression-free survival was deﬁned as the time from transplantation to
relapse, disease progression, or death from any cause. OS and NRM were
calculated using the Kaplan-Meier method. IFD was treated as time-varying
explanatory covariate, and time span records were split (into periods before
and after IFD; “episode splitting”) to account for the effect of IFD on OS and
NRM. This methodology allowed us to compare risks in patients with the
same survival time with and without IFD [28].
Univariate Cox regression models were used to identify signiﬁcant
moderators (independent covariates) on the occurrence of proven/probable
IFD. Time to neutrophil and platelet engraftment was dichotomized at the
75th percentile to deﬁne late engraftments and were included in the anal-
ysis as independent covariates. Variables with a Mantel-Cox P value <.20
were included in the multivariate analysis. Hazard ratios (HRs) with 95%
conﬁdence intervals (CIs) are reported. An HR >1 denotes an unfavorable
effect. A P value <.05 was considered signiﬁcant.RESULTS
Patient Characteristics
A total of 152males and 119 females, with amedian age of
53 years (IQR,18-75 years), were included in the ﬁnal analysis
(Table 1). The most common diagnoses were acute myelog-
enous leukemia (34%), non-Hodgkin lymphoma (24%), mye-
lodysplastic syndrome (15%), acute lymphoblastic leukemia
(8%), and chronic lymphocytic leukemia (5%). Forty patients
(15%) had undergone previous autologous HCT. Eleven
percent of the patients had diabetes, and 6% had a history of
IFD before transplantation. Themedian duration of follow-up
was 16.3months (IQR,1.0-141.0months) posttransplantation.Transplantation Characteristics
Table 2 presents the transplantation characteristics of the
study group. The majority of the patients (64%) received
reduced-intensity or nonmyeloablative pretransplantation
conditioning. The donor source was a fully HLA-matched
sibling donor in 60% of patients, a matched unrelated
donor in 20%, a haploidentical family member in 12%, and
double umbilical cord blood in 8%. All donors and recipients
were typed for HLA-A, -B, and -DRB1. Unrelated donors were
either 7/8 or 8/8 HLA-A, -B, -C, and -DR allele-level matched.
A donor matched for only 3/6, 4/6 or 5/6 alleles was
considered haploidentical. The cord blood units were at least
a 4/6 HLA match with one another and with the recipient.
Using matched-related transplants as reference, matched-
unrelated and haploidentical transplants had higher mean
CD34þ  106 cells/kg infused (namely þ2.6, 95% CI 1.4-3.8,
Table 2
Transplant Characteristics
Characteristic Value
Conditioning regimen, n (%)
Reduced-intensity conditioning 172 (64)
Myeloablative 98 (36)
Donor type, n (%)
Matched related donor 163 (60)
Matched unrelated donor 55 (20)
Haploidentical 32 (12)
Cord 21 (8)
GVHD prophylaxis, n (%)
ATG based 112 (41)
NoneATG-based 158 (59)
CD34þ cell dose,  106 cells/kg, mean  SD 5.10  4.26
Matched related donor 4.52  2.67
Matched unrelated donor 7.15  6.50
Haploidentical 7.23  3.93
Cord blood 0.51  1.58
Time to engraftment, days, median (IQR) 14 (13-17)
Steroid use for GVHD, n (%) 148 (55)
TPN use, n (%) 93 (34)
Figure 1. Spectrum of invasive fungal pathogens.
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P ¼ 0.001 for haploidentical, respectively), whereas cord
blood transplants, as expected had signiﬁcantly lower CD34þ
 106 cells/kg infused (4.0, 95% CI 5.9 to 2.1, P < 0.001).
Engraftment and GVHD
The median time to engraftment was 14 days (IQR, 13-
17 days). The time to engraftment was signiﬁcantly longer in
recipients of cord blood transplantations compared with
recipients of other donor categories (21 days; IQR,17-25 days;
P < .05 for all comparisons). There was a signiﬁcant delay in
engraftment with an infused CD34þ cell dose of <1  106
cells/kg comparedwith a dose of>1106 cells/kg (22 versus
14 days; P< .001, log-rank test), a cutoff that includes all cord
blood transplantations. Platelet engraftment was noted at
a median of 14 days (IQR, 11-19 days). Forty one percent of
patients received ATG-based aGVHD prophylaxis. The
cumulative incidence of grade II-IV aGVHD was 30% and that
of grade III-IV aGVHD was 22%. The cumulative incidence of
chronic GVHD (cGVHD) was 39% (29% limited and 10%
extensive). Fifty-ﬁve percent of the patients received
systemic steroids for GVHD, and 34% received total parenteral
nutrition (TPN) during the course of care.
Prevalence of IFD and Associated Risk Factors
A total of 51 distinct episodes of IFD were observed in 42
patients (15% of patients). Aspergillus spp was the most
frequent causative organism identiﬁed (24/51; 47%), fol-
lowed by Candida spp (22/51, 43%). Mucor was isolated in 1
case, whereas no offending pathogen was isolated in 4 cases.
Among the Candida spp, 50% were non-albicans C glabrata
(n ¼ 8) versus 1 each of C krusei, C tropicalis, and C para-
psilosis (Figure 1).
The most frequently infected site was the lungs (69%),
followed by the bloodstream and paranasal sinuses (14%
each) and gastrointestinal tract (4%). Spleen (hepatosplenic
candidiasis), kidneys, and brain were affected in 1 patient
each. Involvement of both the lungs and sinuses was
observed in 6% of patients.
Risk Factors for IFD
Patient and transplantation factors, including age, diag-
nosis, previous autologous HCT, type of conditioningregimen, type of aGVHD prophylaxis, donor type, CD34þ cell
dose infused, days to neutrophil and platelet engraftment,
history of diabetes or previous IFD, systemic use of steroids
for GVHD, and TPN administration, were examined to
determine risk factors for developing IFD. Multivariate
analysis identiﬁed the use of a haploidentical donor trans-
plantation (HR, 3.82; 95% CI, 1.49-9.77; P ¼ .005) and
development of grade II-IV aGVHD (HR, 2.55; 95% CI, 1.07-
6.10; P ¼ .03) as risk factors for the development of IFD. ATG-
based aGVHD prophylaxis was marginally associated with
increased risk of IFD (HR, 2.01; 95% CI, 1.00-4.04; P ¼ .05).
Conversely, higher CD34þ cell dose was associated with
a lower risk of IFD; the risk of IFD decreased (HR, 0.80; 95% CI,
0.68-0.94; P ¼ .006) with each 1  106 cell/kg increase in
infused CD34þ cell dose. As outlined in Table 3, this lower
risk of IFD with higher CD34þ cell count was independent of
graft source, development of GVHD, and other covariates.
The type of conditioning regimen (reduced-intensity
versus myeloablative) did not affect the risk of developing
IFD after allogeneic HCT (Table 3). Among patients receiving
reduced-intensity conditioning, 7.3% had a history of IFD
before allogeneic HCT, compared with 3.9% in those receiving
myeloablative conditioning. This difference did not reach
statistical signiﬁcance, however (P¼ .24). In a subset analysis,
after excluding patients with a history of IFD before alloge-
neic HCT, the effect of reduced-intensity conditioning
(compared with myeloablative conditioning) on develop-
ment of IFD after allogeneic HCT remained insigniﬁcant (HR,
1.14; 95% CI, 0.62-2.09; P ¼ .67).
For patients developing IFD, the median time to docu-
mented IFD was 174 days post-HCT (IQR, 60-348 days). At
day þ100, the estimated probability of having an IFD was 7%.
Eight of 22 (36%) cases of Candida IFD and 8 of 25 (32%) cases
of Aspergillus IFD were reported before day þ100. The
majority of the IFD cases (67%; 34 of 51) were observed after
day þ100.NRM
The cumulativeNRM ratewas 14.4% (39 of 271), attributed
to severe infections/sepsis (19 cases, including CMV, respi-
ratory syncytial virus, and H1N1 pneumonia, 1 case each),
aGVHD-related complications (10 cases), bleeding compli-
cations (5 cases, including 3 diffuse alveolar hemorrhage and
2 intracranial hemorrhage), posttransplantation lympho-
proliferative disorder (2 cases), T cell lymphoma of donor
origin (1 case), and thromboticmicroangiopathy (1 case). One
patient had missing data on the exact cause of death.
Table 3
Cox Regression Analysis, with IFD as the Dependent Outcome
Variable Univariate Analysis Multivariate Analysis
HR (95% CI) P Value HR (95% CI) P Value
Age 1.00 (0.98-1.02) .70
Male sex 0.93 (0.52-1.67) .82
Previous auto-HCT 1.29 (0.62-2.66) .50
CD34þ cell dose infused 0.88 (0.78-0.99) .03 0.80 (0.68-0.94) .006
Late neutrophil engraftment (>17 days) 1.45 (0.80-2.66) .22
Late platelet engraftment (>19 days) 1.08 (0.54-2.18) .82
Donor type
Matched related 1 (reference)
Matched unrelated 0.84 (0.36-1.94) .68 0.69 (0.26-1.84) .45
Cord blood 2.04 (0.78-5.33) .15 0.47 (0.13-1.65) .24
Haploidentical 1.79 (0.81-3.94) .15 3.82 (1.49-9.77) .005
Reduced-intensity conditioning 1.15 (0.64-2.11) .63
Radiotherapy 0.47 (0.15-1.53) .21
ATG prophylaxis 1.84 (1.03-3.27) .04 2.01 (1.00-4.04) .05
aGVHD
Grade 0-I 1 (reference) 1
Grade II-IV 2.42 (1.36-4.28) .003 2.55 (1.07-6.10) .03
cGVHD
No GVHD 1 (reference)
Limited 0.59 (0.30-1.18) .14 0.62 (0.28-1.39) .25
Extensive 1.08 (0.47-2.50) .85 0.84 (0.32-2.20) .72
Steroids 1.50 (0.82-2.75) .19 1.22 (0.45-3.26) .70
TPN 0.79 (0.43-1.46) .45
Diabetes mellitus 0.51 (0.16-1.66) .27
Previous IFD 0.73 (0.18-3.02) .66
HR >1 denotes an unfavorable effect. Variables with P < .20 were included in the multivariate model.
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probable IFD in the nonrelapse/progression setting. NRM
was signiﬁcantly higher in patients with IFD compared with
those without IFD (P < .001, log-rank test). The estimated
probability of NRM was 4.8% at day þ100, 7.6% at day þ180,
and 11.2% at 1 year post-HCT for patients without IFD,
compared with 25%, 57%, and 71.8%, respectively, for those
with IFD [Figure 2].
OS
At a median follow-up of 16.3 months (range, 1
to141months),125patients haddied (46%). ThemedianOS for
the entire cohort was 44.3 months. Development of IFD was
associated with a worse median OS (5.8 months versus
76.1 months in those without IFD; P < .001, log-rank test)
(Figure 3). The probability of OS was 90.2% at dayþ100, 82.3%
at day þ180, and 71.9% at 1 year posttransplantation forFigure 2. NRM by IFD (Kaplan-Meier failure function estimates; P < .001, log-
rank test).patients without IFD, compared with 80%, 48.9%, and 31%,
respectively, in those with IFD. There was no signiﬁcant
difference in OS between patients with and those without
pretransplantation IFD (median,35months versus44months;
P ¼ .68, log-rank test).
DISCUSSION
The use of HCT is increasing in older, sicker patients as
supportive care techniques have improved. In this study, we
analyzed the risk factors for IFD in recent HCT recipients
receiving either myeloablative or reduced-intensity pre-
transplantation conditioning.
Aspergillus spp cause the majority of non-Candida IFDs
after HCT, and since the introduction of ﬂuconazole for
routine antifungal prophylaxis in HCT, have emerged as the
most frequent causative pathogen of IFD in this population
[4,16,17,29,30]. Although the period of severe neutropenia isFigure 3. Effect of IFD on OS (P < .001, log-rank test).
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aspergillosis in patients receiving standard chemotherapy for
hematologic malignancies [4], several studies have shown
that in HCT recipients, the majority of invasive aspergillosis
cases are reported after day þ100 post-HCT, once full he-
matologic recovery has occurred. This is true for both bone
marrow and peripheral blood graft recipients [4,13,14,29,31-
33]. In our series of patients, we observed a similar trend
with respect to both Candida and Aspergillus IFD. Delayed
time to engraftment was not a signiﬁcant risk factor for IFD.
Our ﬁnding of grade II-IV aGVHD as a signiﬁcant risk factor
for IFD is similar to that reported by Martino et al. [4] and
Wald et al. [31].
Earlier studies involving recipients of allogeneic HCT from
HLA-identical siblings after myeloablative conditioning re-
ported greater morbidity and mortality related to high
infused CD34þ cell dose, owing mainly to an increased risk of
developing extensive cGVHD [34,35]. More recent studies
performed in unrelated allogeneic HCT recipients demon-
strated a more favorable effect of higher CD34þ cell doses
[36-38]. Pulsipher et al. [39], in a large multicenter pro-
spective trial involving 932 pediatric and adult unrelated
peripheral blood HCT recipients with varying conditioning
regimens, reported a decreased risk of NRM and treatment-
related mortality and improved OS, with no increased risk
of GVHD, with a CD34þ cell dose >4.5  106 cells/kg.
Although we did not observe any signiﬁcant associations
between infused CD34þ cell dose and the development of
aGVHD or cGVHD, or between cell dose and OS and NRM, we
did ﬁnd an association between a higher CD34þ cell dose and
a decreased risk of IFD after allogeneic HCT. Bittencourt et al.
[40] reported a similar trend, although that studywas limited
to HLA-identical bone marrow transplantation recipients. In
the present study, the effect of CD34þ cell dose was inde-
pendent of other covariates that we tested, including graft
source and type of conditioning. The exactmechanismof how
a greater CD34þ cell dose affords protection is not entirely
clear. One hypothesis is that a higher infused CD34þ cell dose
leads to earlier immune reconstitution after allogeneic HCT.
We did not study T and B cell immune reconstitution in our
series of patients. Immune reconstitution of T and B cell
lineages can occur up to 12 to 24months after allogeneic HCT.
Delayed immune reconstitution is known to increase the risk
of opportunistic infections [41,42]. Considering that most
cases of IFD occurred after day þ100 post-HCT, once neu-
tropenia had resolved, immune recovery could be a fruitful
area of future investigation.
Male sex and younger donor age are reportedly associated
with a higher CD34þ cell yield after granulocyte colony-
stimulating factor mobilization in healthy donors [43,44].
Multiple studies have identiﬁed plerixafor, a CXC chemokine
receptor 4 antagonist, to be amore potentmobilizing agent for
CD34þ cells compared with granulocyte colony-stimulating
factor, especially in the autologous HCT setting [45-50]. The
use of plerixafor might help augment CD34þ cell dose.
Haploidentical HCT has been shown to confer an
increased risk for opportunistic infections [51], but data on
IFD in haploidentical HCT recipients are limited. This in-
creased risk (a 24% incidence in our series) is likely secondary
to delayed immune reconstitution because of the techniques
used for ex vivo and in vivo T cell depletion, for example, the
use of MEDI-507, posttransplantation cyclophosphamide, or
the anti-CD52monoclonal antibody alemtuzumab to counter
the increased incidence of graft rejection and GVHD in these
mismatched transplantation recipients. A recent study of 291haploidentical HCT recipients without in vitro T cell deple-
tion found a 13.4% incidence of IFD, with themajority of cases
occurring within the ﬁrst 40 days post-HCT [52]. The same
study identiﬁed delayed platelet engraftment (>17 days),
high-risk disease, and grade III-IV GVHD as signiﬁcant risk
factors. A similar (24%) incidence of IFD was seen in among
double cord blood transplantation recipients in our series,
but it did not reach statistical signiﬁcance, most likely
because of the small number of cord blood recipients.
Further research in this area involving larger patient pop-
ulations is needed.
The use of ATG is reportedly associated with an increased
risk of viral infection after HCT [18,53]. In our cohort of
patients, there was a trend toward increased risk of IFD in
patients receiving ATG-based GVHD prophylaxis, but the
difference did not reach statistical signiﬁcance (HR, 2.01; 95%
CI, 1.00-4.04; P ¼ .05) (Table 3). Further studies involving
a larger cohort of subjects are needed to establish the exact
correlation between ATG use and development of IFD after
allogeneic HCT.
Although some studies have reported an increased risk of
IFD with delayed platelet engraftment [52,54,55], we did not
ﬁnd such an association in our series of patients (Table 3).
Cornely et al. [56] described an increased risk of subsequent
IFD and worse outcomes in patients with a previous history
of IFD. A recent study from France found no worse outcomes
in patients with a previous history of aspergillosis who
received reduced-intensity allogeneic HCT [57]. Maziarz et al.
[58] analyzed the Center for International Blood and Marrow
Transplant Research database from multiple transplantation
centers and in a preliminary analysis reported an increased
risk for subsequent IFD and worse disease-free survival and
OS for patients with a history of IFD undergoing allogeneic
HCT for advanced acute myelogenous leukemia, acute lym-
phoblastic leukemia, myelodysplastic syndrome, and chronic
myelogenous leukemia. In our series of patients, a previous
history of IFD did not confer a signiﬁcantly higher risk of
subsequent IFD, and these patients did not do worse
compared with those with no history of pretransplantation
IFD. This ﬁnding indicates that a history of previous IFD
should not be considered a contraindication for allogeneic
HCT. The discrepant ﬁndings might be related to the fact that
the present study is a single-institution study involving
a smaller number of patients. In addition, our patients
received allogeneic HCT for a greater variety of hematologic
malignancies (approximately one-third had non-Hodgkin
lymphoma/Hodgkin disease or multiple myeloma) com-
pared with the patient population analyzed by Maziarz
et al. [58].
A contributing factor to the late onset of IFD could be the
antifungal prophylaxis protocol in place. Fluconazole was
used from the day before transplantation until at least
day þ100, to cover the period of neutropenia and initial
immunosuppression. Considering that the majority of IFD
cases occurred after day þ100, with Aspergillus spp the
primary pathogens, further research in this area is needed to
establish whether antifungal prophylaxis, speciﬁcally
directed against aspergillus (eg, micafungin, voriconazole, or
itraconazole) should be continued beyond day þ100. Con-
comitant use of these azoles, which inhibit the cytochrome
P450 3A isoenzyme, with sirolimus necessitates careful
dosage adjustments and close monitoring of sirolimus
trough levels [59,60]. A recent multicenter, randomized,
open-label phase III study by Huang et al. [61] involving 287
subjects reported similar efﬁcacy but better tolerability of
A.K. Omer et al. / Biol Blood Marrow Transplant 19 (2013) 1190e1196 1195micafungin compared with itraconazole in preventing IFD
among HCT recipients with neutropenia.
The present study has several limitations, including its
retrospective nature, the number of patients studied, and the
variety of conditioning regimens, GVHD prophylaxis, and graft
sources used. We were unable to determine the effect of
antifungal prophylaxis givenduring leukemia inductionon the
development of IFD after allogeneic HCT. We did not discuss
treatment of IFD or immune reconstitution data. We included
only proven and probable cases of IFD based on standard
deﬁnitions [24] and did not include possible IFD cases, which
might have led to underestimation of the actual incidence.
In summary, IFD is a major complication after allogeneic
HCT, with a high infection-related mortality. Grade II-IV
aGVHD and haploidentical HCT are risk factors for the
development of IFD. A high infused CD34þ cell dose reduces
the risk of IFD. Further studies examining alternative aGVHD
prophylaxis regimes and adequate antifungal prophylaxis,
especially against Aspergillus, beyond day þ100 post-HCT are
needed for high-risk patients with clinically signiﬁcant
GVHD, to prevent the development of IFD. In addition,
exploring strategies for increasing the infused CD34þ cell
dose could help decrease the incidence of this potentially
life-threatening complication after allogeneic HCT.ACKNOWLEDGMENTS
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